GSK , Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, a ...

GSK, Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, ...

CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the ...

Sanofi (SNY), and CSL (CSLLY) win $72M U.S. contract to expand bird flu vaccine production amid fears of human transmission.

The U.S. government has granted $72 million to European pharma giants GSK Plc (NYSE:GSK), Sanofi SA (NASDAQ:SNY) and ...

Australia's CSL said on Wednesday it has got a contract from the U.S. Department of Health and Human Services (HHS) worth ...

US has announced team up with multinational pharmaceutical companies CSL, GSK, Sanofi, and Seqirus for a $72 million worth of ...

CSL shares have been heavily sold and now rest near their three-month lows. Is now the time to buy? Let's see what the ...

At the current CSL share price, this ASX 200 healthcare giant is trading on a dividend yield of 0.97%. Motley Fool investing ...

Vaccine maker CSL Seqirus has lined up yet another contract with the U.S. | With a $121.4 million award from the U.S.

CSL's revenue has fluctuated over the last three years, with a decline in 2023 due to market instability. Read why I rate CSL ...

Investors Mutual’s Daniel Moore says there aren’t too many ASX-listed companies like blood plasma giant CSL that can compound ...